Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations

Vaccine

Volumn 33, Issue 1, 2015, Pages 163-173

  Frey, Sharon E ^a   Bernstein, David I ^b   Brady, Rebecca C ^b   Keitel, Wendy A ^c   Sahly, Hana El ^c   Rouphael, Nadine Georges ^d   Mulligan, Mark J ^d   Atmar, Robert L ^c   Edupuganti, Srilatha ^d   Patel, Shital M ^c   Dickey, Michelle ^b   Graham, Irene ^a   Anderson, Edwin L ^a   Noah, Diana L ^e   Hill, Heather ^f   Wolff, Mark ^f   Belshe, Robert B ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f EMMES CORPORATION   (United States)

Author keywords

2009 H1N1; Adults; Concurrent; Elderly; HAI; Influenza vaccine; Microneutralization; Pandemic; Seasonal IIV3; Sequential

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; PLACEBO; VIRUS ANTIBODY;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GROUPS BY AGE; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; IMMUNOGENICITY; IMMUNOREACTIVITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALAISE; MALE; NORMAL HUMAN; PANDEMIC INFLUENZA; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; HEMAGGLUTINATION INHIBITION TEST; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; VACCINATION; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PLACEBOS; VACCINATION; YOUNG ADULT;

EID: 84919383172     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.10.083     Document Type: Article

References (32)

1. Garten R.J., Davis C.T., Russel C.A., Shu B., Lindstrom S., Balish A., et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009, 325:197-201.
2. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615. [Erratum, N Engl J Med 2009;361:102.].
3. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009, 361:1935-1944.
4. France A.M., Jackson M., Schrag S., Lynch M., Zimmerman C., Biggerstaff M., et al. Household transmission of 2009 influenza A (H1N1) virus after a school-based outbreak in New York City, April-May 2009. J Infect Dis 2010, 201:984-992.
5. Centers for Disease control and Prevention Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:453-458.
6. Centers for Diseases Control and Prevention Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009, 58:521-524.
7. Hancock K., Veguilla V., Lu X., Zhong W., Butler E.N., Sun H., et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361:1945-1952.
8. Wu J., Xu F., Lu L., Lu M., Miao L., Gao T., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 2010, 363:2416-2423.
9. Zhu F.-C., Wang H., Fang H.-H., Yang J.G., Lin X.J., Liang X.F., et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009, 361:2414-2423.
10. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N Engl J Med 2010, 362:370-372.
11. Talaat K.R., Greenberg M.E., Lai M.H., Hartel G.F., Wichens C.H., Rockman S., et al. A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. J Infect Dis 2010, 202:1327-1337.
12. Greenberg M.E., Lai M.H., Hartel G.F., Wichens C.H., Gittleson C., Bennet J., et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009, 361:2405-2413.
13. Madhun A.S., Akselsen P.E., Sjursen H., Pedersen G., Svindland S., Nøstbakken J.K., et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010, 29:266-273.
14. Clark T.W., Pareek M., Hoschler K., Dillon H., Nicholson K.G., Groth N., et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009, 361:2424-2435.
15. Mallory R.M., Malkin E., Ambrose C.S., Bellamy T., Shi L., Yi T., et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE 2010, 5:e13755.
16. Frey S.E., Bernstein D.I., Gerber M.A., Keyserling H.L., Munoz F.M., Winokur P.L., et al. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis 2012, 206:828-837.
17. Nolan T., McVernon J., Skeljo M., Richmond P., Wadia U., Lambert S., et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in infants and children: a randomized trial. JAMA 2010, 303:37-46.
18. Noah D.L., Hill H., Hines D., White E.L., Wolff M.C. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vacc Immunol 2009, 16:558-566.
19. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
20. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/vaccines/ucm074786.htm.
21. Jackson L.A., Chen W.H., Stapleton J.T., Dekker C.L., Wald A., Brady R.C., et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis 2012, 206:811-820.
22. Chen W.H., Winokur P.L., Edwards K.M., Jackson L.A., Wald A., Walter E.B., et al. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine 2012, 30:4240-4248.
23. Liang X.F., Wang H.Q., Wang J.Z., Fang H.H., Wu J., Zhu F.C., et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomized, placebo-controlled trial. Lancet 2010, 375:56-66. [Erratum, Lancet 2010;375:1694].
24. Kulkarni P.S., Manjunath K., Agarkhedkar S., Group of S.I.I., Studies I.I.V. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine 2012, 31:20-22.
25. A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial. BMC Infect Dis 2012, 12:162.
26. Miraglia J.L., Abdala E., Hoff P.M., Luiz A.M., Oliveira D.S., Saad C.G.S., et al. Immunogenicity and reactogenicity of 2009 influenza A (H1N1) inactivated monovalent non-adjuvanted vaccine in elderly and immunocompromised patients. PLoS ONE 2011, 6:e27214.
27. Viganò A., Giacomet V., Pariani E., Giani E., Manfredini V., Bedogni G., et al. Long-term immunogenicity after one and two doses of a monovalent MF59-adjuvanted A/H1N1 Influenza virus vaccine coadministered with the seasonal 2009-2010 nonadjuvanted Influenza virus vaccine in HIV-infected children, adolescents, and young adults in a randomized controlled trial. Clin Vaccine Immunol 2011, 18:1503-1509.
28. Peeters M., Regner S., Vaman T., Devaster J-M., Rombo L. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicenter randomised trials. Vaccine 2012, 30:6483-6491.
29. Vajo Z., Tamas F., Sinka L., Jankovics I. Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. Lancet 2010, 375:49-55.
30. Langley J.M., Frenette L., Chu L., McNeil S., Halperin S., Li P., et al. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine. BMC Infect Dis 2012, 12:279.
31. Uno S., Kimachi K., Kei J., Miyazaki K., Oohama A., Nishimura T., et al. Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial. Microbiol Immunol 2011, 55:783-789.
32. Levine M., Beattie B.L., McLean D.M., Corman D. Characterization of the immune response to trivalent influenza vaccine in elderly men. J Am Geriatr Soc 1987, 35:609-615.